Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5328859 | 0.83 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL9844054 | 0.62 | HCAR2 (0.71) | HCAR2 | |
| SCHEMBL3100024 | 0.59 | RORA (0.59) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1713448 | 0.59 | HTT (0.75) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2076414 | 0.59 | ELANE (0.47) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL23398967 | 0.59 | MEN1 (0.52) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL10528152 | 0.59 | F2 (0.43) | HCAR2 | |
| SCHEMBL1567707 | 0.59 | HTT (0.51) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19897480 | 0.59 | PGR (0.49) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7645564 | 0.59 | ADORA2B (0.42) | PDE4APDE4BPDE4CPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-5565482-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | G.D. SEARLE & CO. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5547975-A | ANTIARTHRIC AGENTS, ANALGESICS AND ANTIPYRETICS; INHIBITORS OF CYCLOOXYGENASE II; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 1996-08-20 | — | — | US | disclosed |
| WO-1996009304-A1 | BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | HTT 2432/4885PDE4A 1888/4885PDE4B 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.